```html

Zollinger‑Ellison–type Neuroendocrine Tumor (NET)

Overview

Zollinger‑Ellison–type neuroendocrine tumors are a rare subset of pancreatic neuroendocrine tumors (PNETs) that secrete excessive amounts of the hormone gastrin. The resulting condition is called Zollinger‑Ellison syndrome (ZES), characterized by severe, peptic‑ulcer disease and watery diarrhea. These tumors arise from enterochromaffin‑like (ECL) cells in the pancreas or, less commonly, in the duodenum.

Although neuroendocrine tumors account for <1 % of all malignancies, gastrin‑producing (Zollinger‑Ellison) tumors represent only about 0.5 %–1 % of all NETs <sup>1</sup>. Most cases are diagnosed between the ages of 30 and 60, with a slight male predominance (55 % male) and a higher incidence in individuals of European descent. Familial cases (≈25 %) occur in patients with multiple endocrine neoplasia type 1 (MEN‑1).

Symptoms

Because excess gastrin hyper‑stimulates stomach acid production, the clinical picture can be dramatic. Symptoms may be intermittent at first and become continuous as the tumor grows.

Gastro‑intestinal (GI) symptoms

• Refractory peptic ulcers: Ulcers that do not heal with standard therapy, often multiple and located in atypical sites (duodenum, jejunum).
• Epigastric or upper abdominal pain: Burning or gnawing pain that worsens 2–3 hours after meals.
• Acid‑related regurgitation & heartburn: Persistent gastro‑esophageal reflux despite proton‑pump inhibitor (PPI) use.
• Diarrhea: Watery, non‑bloody stools; can be secretory (≥3 L/day in severe cases).
• Steatorrhea (fatty stools): Malabsorption due to acid inactivation of pancreatic enzymes.
• Nausea & vomiting: Often triggered by high‑acid load.

Systemic symptoms

• Weight loss: Secondary to malabsorption and chronic diarrhea.
• Fatigue: From anemia (iron deficiency) or chronic disease.
• Facial flushing or itching: Rare, due to vasoactive peptide release.
• Electrolyte disturbances: Low potassium and magnesium from chronic diarrhea.

Signs of tumor burden

• Palpable abdominal mass: Usually only in advanced disease.
• Metastatic symptoms: Liver involvement may cause right‑upper‑quadrant pain, jaundice, or hepatic insufficiency.

Causes and Risk Factors

Primary causes

• Genetic mutations: Inactivating mutations of the MEN1 gene are the most common hereditary cause. Sporadic tumors often harbor VHL, NF1, or RET alterations.
• Neuroendocrine cell hyperplasia: Chronic hypergastrinemia (e.g., from H. pylori infection or long‑term PPI use) can stimulate ECL cell proliferation, but this alone rarely leads to a Zollinger‑Ellison tumor.

Risk factors

• Family history of MEN‑1 or other hereditary endocrine tumor syndromes.
• Known pancreatic NETs of any type (increased surveillance is warranted).
• Age 30‑60 (peak incidence).
• Male sex (modest increased risk).
• Chronic H. pylori infection – contributes to gastrin elevation, though not a direct cause of the tumor.

Diagnosis

Diagnosis requires a combination of biochemical, imaging, and histologic studies.

Biochemical testing

• Fasting serum gastrin level: Levels > 10× upper‑limit of normal (typically > 1000 pg/mL) in the presence of gastric acid hypersecretion strongly suggest ZES.
• Secretin stimulation test: Administration of secretin causes a paradoxical rise in gastrin in ZES (increase > 120 pg/mL). This test helps differentiate ZES from other causes of hypergastrinemia.
• Chromogranin A (CgA): A general NET marker; elevated in > 70 % of patients but can be false‑positive with proton‑pump inhibitor use.

Imaging studies

• Endoscopic ultrasound (EUS): Highly sensitive for detecting small pancreatic or duodenal lesions (≤1 cm).
• Multiphasic contrast‑enhanced CT or MRI: Provides anatomic detail, assesses local invasion and distant metastasis.
• Somatostatin receptor imaging (68Ga‑DOTATATE PET/CT): Gold‑standard functional imaging; highlights tumors expressing somatostatin receptors, useful for staging and therapy planning.
• Selective arterial secretin stimulation test (SASS): Invasive but can localize occult tumors when non‑invasive imaging is negative.

Pathology

If a lesion is resected or biopsied, histology will typically show nests or trabeculae of uniform neuroendocrine cells positive for gastrin, chromogranin A, and synaptophysin on immunohistochemistry. Ki‑67 proliferative index classifies the tumor grade (G1 ≤ 2 %, G2 = 3‑20 %, G3 > 20 %).

Treatment Options

Therapy is individualized based on tumor size, grade, location, and presence of metastases.

Medical management

• Proton‑pump inhibitors (PPIs): High‑dose PPIs (e.g., omeprazole 40‑80 mg daily) are the mainstay for controlling acid hypersecretion and ulcer disease. Dose titration is guided by symptom control and gastric pH monitoring.
• H2‑receptor antagonists: May be added for breakthrough symptoms, but PPIs are superior.
• Somatostatin analogues (SSA): Octreotide or lanreotide bind somatostatin receptors, reducing gastrin secretion and may shrink tumor burden, especially in metastatic disease.
• Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for progressive, well‑differentiated pancreatic NETs; they can be considered when SSA alone is insufficient.
• Chemotherapy: Streptozocin‑based regimens, capecitabine‑temozolomide (CAPTEM), or platinum‑etoposide for high‑grade (G3) tumors.

Surgical options

• Curative resection: Enucleation, pancreaticoduodenectomy (Whipple), or distal pancreatectomy, depending on tumor location. Up to 80 % of patients with localized disease become long‑term disease‑free after complete resection.
• Liver metastasectomy or ablative therapies: For limited hepatic disease, resection, radiofrequency ablation, or microwave ablation can improve survival.
• Hepatic artery embolization (HACE) / Radioembolization (Y‑90): Palliative for extensive liver metastases, controlling tumor growth and hormone secretion.

Lifestyle & supportive care

• Avoid alcohol and tobacco, which aggravate ulcer disease.
• Small, frequent meals and low‑fat diet to reduce post‑prandial acid load.
• Supplement iron, vitamin B12, and fat‑soluble vitamins (A, D, E, K) if malabsorption is present.
• Regular monitoring of bone density—chronic acid suppression can affect calcium absorption.

Living with Zollinger‑Ellison–type Neuroendocrine Tumor

Follow‑up schedule

• Every 3–6 months: serum gastrin, chromogranin A, and basic metabolic panel.
• Annual imaging (CT/MRI or 68Ga‑DOTATATE PET) to assess for recurrence.
• Endoscopic evaluation every 1–2 years if ulcer disease persists.

Practical daily tips

• Medication adherence: Take PPIs 30 minutes before breakfast; never skip doses.
• Hydration: Replace fluids lost through diarrhea; oral rehydration solutions with electrolytes are helpful.
• Symptom diary: Track pain, stool frequency, and medication response; share with your gastroenterologist.
• Stress management: Chronic stress can increase gastrin secretion—practice relaxation techniques, yoga, or mindfulness.
• Support networks: Join NET patient groups (e.g., NET Patients Network) for emotional support and up‑to‑date information.

Prevention

Because most Zollinger‑Ellison tumors are sporadic or genetically predetermined, primary prevention is limited. However, the following measures may reduce overall risk of NET development or progression:

• Screen individuals with known MEN‑1 or familial NETs with regular biochemical testing (fasting gastrin) and imaging.
• Eradicate Helicobacter pylori infection to lower basal gastrin levels.
• Limit long‑term, high‑dose PPI use in people without a clear indication—counter‑intuitive, but chronic hypergastrinemia from PPI overuse is a theoretical risk for enterochromaffin‑like cell hyperplasia.
• Maintain a healthy weight, balanced diet, and avoid tobacco and excessive alcohol.

Complications

If left untreated or poorly controlled, Zollinger‑Ellison–type NETs can lead to serious health problems:

• Refractory peptic ulcer disease: Perforation, hemorrhage, or stricturing requiring emergency surgery.
• Severe diarrhea & electrolyte imbalance: Dehydration, renal insufficiency, arrhythmias.
• Gastric outlet obstruction: From ulcer scarring.
• Metastatic spread: Liver is the most common site; can cause hepatic failure.
• Reduced bone density: Chronic acid suppression impairs calcium absorption, increasing fracture risk.
• Malnutrition: Due to chronic malabsorption and catabolic state.

When to Seek Emergency Care

References

• 1. National Comprehensive Cancer Network. Neuroendocrine and Non‑Neuroendocrine Tumors of the Pancreas. 2024.
• 2. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023.
• 3. Nishinaka, Y. et al. “Management of gastrin‑producing neuroendocrine tumors.” Journal of Gastroenterology, 2022.
• 4. European Neuroendocrine Tumor Society (ENETS) Guidelines for Pancreatic NETs, 2023.
• 5. NIH National Cancer Institute. “Pancreatic Neuroendocrine Tumors (PNET).” Accessed June 2024.

```